Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of ...

On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and ...

Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus - - Mary Beth ...

IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...

Fintel reports that on October 1, 2024, Truist Securities downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from ...

Fintel reports that on October 1, 2024, JP Morgan downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Neutral ...

Wedbush analyst Robert Driscoll maintained a Buy rating on IGM Biosciences (IGMS – Research Report) today and set a price target of ...

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...

On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for ...

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower ...

The presence of antibodies without viral antigen or DNA. The presence of IgG anti-HBcAb but lack of IgM anti-HBcAb antibody (in our case, we tested for IgG only. Given the predominance of IgG in ...